Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial - De Leeuw, Elisabeth; Van Damme, Karel F. A.; Declercq, Jozefien; Bosteels, Cedric; Maes, Bastiaan; Tavernier, Simon J.; Detalle, Laurent; Smart, Trevor; Glatt, Sophie; Debeuf, Nincy; Deckers, Julie; Lameire, Sahine; et al. (Respiratory research, 2022)
Keywords: Anti-Infective Agents; Antibiotics; Biological response modifiers; Complement (Immunology); Complement 5; Complement C5; Complement component C5; Complement Inactivating Agents; Complement Inactivating Agents - adverse effects; Complement system; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Drug therapy; Effectiveness; Female; Health aspects; Hospital patients; Hospitalization; Human health sciences; Humans; Hypoxemia; Immunologie & maladie infectieuse; Immunology & infectious disease; Inflammation; Inhibitors; Interleukin 8; Interleukins; Male; Mean; Middle Aged; Mortality; Nosocomial infections; Oxygenation; Patients; Peptides, Cyclic; Prophylaxis; Proteins; Pulmonary and Respiratory Medicine; Respiratory function; Safety; SARS-CoV-2; Sciences de la santé humaine; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Systemic inflammation; Testing; Treatment Outcome; Ventilators; zilucoplan; Belgium; COVID-19; Complement system; Complement 5; Systemic inflammation